Skip to content
Screener

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
5.3×-0.2×
Gilead Sciences logo
Gilead SciencesGILD
13.3×+6.5×
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
2.7×+2.3×
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
5.7×+0.9×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
1.5×+0.3×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
3.6×-5.6×

Other financials

Income statement

See full
Revenue-
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation

See full
Market cap$550.99M+783%
Enterprise value$258.93M+455%

Profitability

See full
Operating margin-83.9%
Net margin-79.3%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity-0.1×
Current ratio24.2×+10.3×

Where this comes from

Calculated from Artiva Biotherapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338029

FAQ

What is Artiva Biotherapeutics, Inc.'s price / book?
Artiva Biotherapeutics, Inc. (ARTV) reported price / book of 1.4× in Q2 2026.
How has Artiva Biotherapeutics, Inc.'s price / book changed year-over-year?
Artiva Biotherapeutics, Inc.'s price / book increased by 415.3% year-over-year, from 0.3× to 1.4×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Artiva Biotherapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude